BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Flexible Stenting Solutions Inc. Lands CE Mark for It's Self-Expanding Stent System


12/27/2012 7:32:03 AM

EATONTOWN, N.J.--(BUSINESS WIRE)-- Flexible Stenting Solutions, Inc. (“FSS”) is pleased to announce that it is now authorized to CE Mark and market its 6 Fr Reconstrainable FlexStent® Self-Expanding Stent System in the European Union. FSS is a leading developer of next-generation peripheral, neurovascular and biliary stents. This new device combines the advanced FlexStent® technology with unique reconstrainable stent delivery technology.

Reconstrainability enables the physician to fully recapture then reposition a partially deployed stent. Based on ongoing market research and physician feedback, FSS believes reconstrainability will be a powerful tool for optimizing stent placement in challenging vascular anatomies thereby enhancing overall patient safety. The Reconstrainable FlexStent® Femoropopliteal Self Expanding Stent System is indicated for the treatment of symptomatic atherosclerotic disease of the femoropopliteal arteries. Stent and system sizes include stent diameters of 5, 6, 7, and 8 mm in lengths of 30 to 200 mm with delivery system lengths of 80 cm and 120 cm, as originally CE Mark authorized with the standard delivery system.

FSS intends to apply this novel reconstrainable delivery technology across its platform of current and future stent products. With the elegant and user-friendly reconstrainable delivery system, the complete FlexStent® family of stents can be delivered with the same simplicity and low force demonstrated by the standard delivery system. Recapture and secondary deployment of the stent in the reconstrainable system are both accomplished with equal ease and simplicity.

Janet Burpee, FSS’s CEO, commented, “Our engineers and Chief Operating Officer, Bradley Beach, have exceeded my expectations in creating this novel delivery system.” She further stated that “FSS is always patient focused; we are very excited about this advanced safety feature.”

About Flexible Stenting Solutions Inc.

Flexible Stenting Solutions Inc. (FSS) is a leading developer of third-generation flexible peripheral arterial, venous, neurovascular and biliary stents, and reconstrainable delivery systems. Its nearly fully connected stent has coupled technology with clinical needs by providing an atraumatic, highly durable and fatigue resistant stent with superior radial stiffness, flexibility and conformability. FSS is an ISO 13485:2003 certified company.

For further information on Flexible Stenting Solutions, please visit the company website at www.flexiblestent.com.

FlexStent® is a registered trademark of Flexible Stenting Solutions, Inc.

Contact:

Flexible Stenting Solutions, Inc.

Janet Burpee, 732-578-0060



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES